Nobel-winning light technology targets seizure-causing brain cells

The 2026 Nobel Prize in Physiology or Medicine was awarded for optogenetics, a light-based technology that could enable precise treatment of drug-resistant epilepsy by switching off seizure-causing brain cells. This approach offers a potential new option for patients where medications fail. Optogenetics uses light-sensitive proteins called opsins to activate or silence specific neurons with millisecond precision, allowing doctors to target hyperactive cells that generate seizures. Experts say it could also help map neural circuits in conditions like depression, Parkinson's disease, and addiction, with human trials already underway for eye diseases. The technology, derived from studies of light-sensitive proteins in algae, remains largely at the laboratory and animal-study stage. Widespread clinical use faces challenges in safely delivering proteins and light to targeted brain cells, though research is progressing at centers like the University of California.